3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Primary Myelofibrosis
19
Myeloproliferative Disorders
16
Polycythemia Vera
10
Leukemia
8
Leukemia, Myeloid, Acute
7
Breast Neoplasms
6
Pancreatic Neoplasms
5
Myelodysplastic Syndromes
5
Hematologic Diseases
5
Thrombocythemia, Essential
4
Multiple Myeloma
4
Bone Marrow Diseases
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Myelodysplastic-Myeloproliferative Diseases
3
Leukemia, Myelomonocytic, Chronic
3
Graft vs Host Disease
3
Thrombocytosis
2
Prostatic Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Bronchiolitis Obliterans Syndrome
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Preleukemia
1
Precancerous Conditions
1
Pathologic Complete Response
1
Interventions
Rituximab
131
Cyclophosphamide
74
fludarabine phosphate
51
Whole-Body Irradiation
38
Peripheral Blood Stem Cell Transplantation
36
Mycophenolic Acid
36
Tacrolimus
32
Etoposide
28
Busulfan
28
Melphalan
24
Lenalidomide
23
Prednisone
22
Filgrastim
22
Cyclosporine
22
Bortezomib
22
Antilymphocyte Serum
21
Vincristine
19
Methotrexate
19
obinutuzumab
17
Bendamustine Hydrochloride
16
fludarabine
15
Doxorubicin
15
Radiotherapy
14
ibrutinib
13
Dexamethasone
13
Cytarabine
13
Cord Blood Stem Cell Transplantation
13
Carmustine
13
pembrolizumab
12
idelalisib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Follicular
×
ruxolitinib
×
Clear all
NCT03774082
2025-12-11
REACH 5
Novartis
Phase 2
Completed
46 enrolled
21 charts
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts